Karyopharm Therapeutics

Historical price data

Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.

Oral Selective Inhibitor of Nuclear Export (SINE) platform targeting the nuclear export protein XPO1, a fundamental mechanism in oncogenesis that forces nuclear retention of tumor suppressor proteins and induces cancer cell apoptosis.

Karyopharm faces intense competition from novel modalities (bispecifics, CAR-T) in myeloma and lymphoma, and from JAK inhibitors in myelofibrosis. Its key advantage is first-mover status with a novel, oral XPO1 inhibitor mechanism, but it must continuously demonstrate differentiated efficacy and tolerability against evolving standards of care.